Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Company Deals

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

Fineline Cube May 9, 2026
Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors

Fineline Cube May 9, 2026
Company Drug

Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda

Fineline Cube May 9, 2026
Policy / Regulatory

China Unveils Management Measures to Strengthen National Health Emergency Teams

Fineline Cube Mar 28, 2024

The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control...

Hospital Policy / Regulatory

China’s NHC Mandates Enhanced Management and Accessibility of Midwifery Services

Fineline Cube Mar 28, 2024

The National Health Commission (NHC) has issued a notification with the aim of enhancing the...

Company Medical Device

AstraZeneca’s Tralokinumab Trial Data Spurs Development of Brainomix’s e-Lung Software

Fineline Cube Mar 28, 2024

AstraZeneca (AZ; NASDAQ: AZN) has reported data from a Phase II trial for its idiopathic...

Company Deals

BeiGene Terminates Partnership with Shoreline Therapeutics for NK Cell Therapies

Fineline Cube Mar 28, 2024

A close examination of BeiGene’s (NASDAQ: BGNE; HKG: 6160; SHA: 688235) recent annual report has...

Company

Luye Pharma Group Posts 2.7% YOY Revenue Growth in 2023 with Strong Market Performance

Fineline Cube Mar 28, 2024

Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced its...

Company

MicroPort CardioFlow Medtech Reports 33.9% YOY Revenue Growth in 2023 Financials

Fineline Cube Mar 28, 2024

MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG:...

Company

Ascentage Pharma Reports 5.9% YOY Revenue Growth in 2023, Driven by Product Sales

Fineline Cube Mar 28, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has released its financial report...

Company

CanSino Biologics Reports 2023 Revenue Dip Amid Reduced COVID-19 Vaccine Demand

Fineline Cube Mar 28, 2024

CanSino Biologics (HKG: 6185), a leading Chinese biopharmaceutical company, has released its financial report for...

Company Deals

Recbio and Rongsheng Biotech Join Forces to Develop New Adjuvant Vaccine Technologies

Fineline Cube Mar 28, 2024

Jiangsu Recbio Technology Co., Ltd (HKG: 2179) and Shanghai Rongsheng Biotech Co., Ltd have announced...

Medical Device R&D

Tianjin University Team Develops Self-Sustaining Na-O2 Battery for Implantable Devices

Fineline Cube Mar 28, 2024

Researchers at China’s Tianjin University of Technology have made a groundbreaking advancement with the development...

Company Drug

Zai Lab and Novocure Report Positive Phase III Results for TTFields in NSCLC Brain Metastases

Fineline Cube Mar 28, 2024

Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a biopharmaceutical company based in China, and Novocure...

Company Deals

Merck Expands Global Footprint with Largest M Lab Collaboration Center in Shanghai

Fineline Cube Mar 27, 2024

Merck KGaA (ETR: MRK), a leading German technology company, has announced the completion of the...

Company Deals

Kangtai Biological Partners with AstraZeneca and Beijing Daxing District to Boost Vaccine Market Presence

Fineline Cube Mar 27, 2024

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a prominent biopharmaceutical company based in China,...

Company Drug

Jiangsu Hengrui Receives NMPA Approval for SHR-7631 ADC Clinical Study in Solid Tumors

Fineline Cube Mar 27, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

Wuhan YZY Biopharma Initiates Phase II Study for M701 in Malignant Pleural Effusion Treatment

Fineline Cube Mar 27, 2024

Wuhan YZY Biopharma Co., Ltd (HKG: 2496), a biopharmaceutical company based in China, has announced...

Company Medical Device

Acotec Scientific Receives NMPA Approval for Innovative Cardiovascular Devices

Fineline Cube Mar 27, 2024

Acotec Scientific Holdings Ltd (HKG: 6669), a leading medical device company based in China, has...

Company

Sanofi Launches KiDS Program in China to Boost Health Literacy in Schools

Fineline Cube Mar 27, 2024

Olivier Charmeil, Executive Vice-President for General Medicines at France-based Sanofi S.A. (NASDAQ: SNY), visited China...

Company

WuXi Bio Reports 2023 Revenue Growth Amid COVID-19 Business Loss and Geopolitical Tensions

Fineline Cube Mar 27, 2024

WuXi Bio (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...

Company Drug

Innovent Biologics Initiates Phase III Neoshot Study for MSI-H/dMMR Colon Cancer Treatment

Fineline Cube Mar 27, 2024

Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...

Company Drug

Alexion’s Ultomiris Secures FDA Approval for Anti-AQP4 Positive NMOSD Treatment

Fineline Cube Mar 27, 2024

AstraZeneca’s (AZ; NASDAQ: AZN) rare disease unit, Alexion, has registered its biologic Ultomiris (ravulizumab) with...

Posts pagination

1 … 379 380 381 … 662

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors
  • Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda
  • Ab&B Bio-Tech Secures NMPA Clinical Approval for mRNA RSV Vaccine, Addressing Critical Unmet Need in China
  • Mabwell Bioscience Secures FDA Clearance for 9MW5211 in IBD, Advances Multi-Indication Autoimmune Pipeline
  • Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors

Company Drug

Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda

Company Drug

Ab&B Bio-Tech Secures NMPA Clinical Approval for mRNA RSV Vaccine, Addressing Critical Unmet Need in China

Company Drug

Mabwell Bioscience Secures FDA Clearance for 9MW5211 in IBD, Advances Multi-Indication Autoimmune Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.